In yesterday’s Wall Street session, Gossamer Bio Inc. (NASDAQ:GOSS) shares traded at $1.31, down -1.50% from the previous session.
13 analysts cover Gossamer Bio Inc. (NASDAQ:GOSS), according to research data. The consensus rating among analysts is ‘Overweight’. As we calculate the median target price by taking the range between a high of $15.00 and a low of $1.50, we find $5.50. Given the previous closing price of $1.33, this indicates a potential upside of 313.53 percent. GOSS stock price is now 8.04% away from the 50-day moving average and -78.14% away from the 200-day moving average. The market capitalization of the company currently stands at $116.01M.
25-cent Stock Takes $11T Commodities Sector Digital
One brilliantly-run technology firm has successfully partnered with some of the largest players in the industry to bring a first-of-its-kind digital solution to the global commodities supply chain sector. Best of all, this upstart technology firm is currently trading undiscovered — below 25-cents per share — so very, very few investors know about it yet! For investors… it's an early-stage opportunity in a company that's bringing the US$11T global commodities sector straight into the 21st century.
All the details are in the FREE online report you can get here.
The stock has received a hold rating from 3 analysts and a buy rating from 9. Brokers who have rated the stock have averaged $6.35 as their price target over the next twelve months.
In other news, Giraudo Bryan, COO/CFO bought 55,000 shares of the company’s stock on Apr 04. The stock was bought for $56,094 at an average price of $1.02. Upon completion of the transaction, the COO/CFO now directly owns 125,990 shares in the company, valued at $0.17 million. An SEC document containing details of the transaction can be found on the SEC’s website. On Mar 22, President & CEO Hasnain Faheem bought 440,500 shares of the business’s stock. A total of $503,580 was incurred on buying the stock at an average price of $1.14. This leaves the insider owning 4,495,897 shares of the company worth $5.89 million. Insiders disposed of 51,008 shares of company stock worth roughly $66820.48 over the past 1 year. A total of 1.20% of the company’s stock is owned by insiders.
There have been several recent changes in the stakes of large investors in GOSS stock. A new stake in Gossamer Bio Inc. shares was purchased by CITADEL ADVISORS LLC during the first quarter worth $3,661,000. PLATINUM INVESTMENT MANAGEMENT LTD invested $3,096,000 in shares of GOSS during the first quarter. In the first quarter, ERGOTELES LLC acquired a new stake in Gossamer Bio Inc. valued at approximately $2,269,000. HRT FINANCIAL LP acquired a new stake in GOSS for approximately $2,028,000. CENTIVA CAPITAL, LP purchased a new stake in GOSS valued at around $348,000 in the second quarter. In total, there are 175 active investors with 118.76% ownership of the company’s stock.
During the past 12 months, Gossamer Bio Inc. has had a low of $0.91 and a high of $15.19. The fifty day moving average price for GOSS is $1.2123 and a two-hundred day moving average price translates $5.9352 for the stock.
The latest earnings results from Gossamer Bio Inc. (NASDAQ: GOSS) was released for Mar, 2023. According to the Biotechnology Company, earnings per share came in at -$0.52, beating analysts’ expectations of -$0.53 by 0.01. This compares to -$0.76 EPS in the same period last year. The company reported revenue of $47.94 million for the quarter, compared to $54.34 million a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue fell -11.78 percent.
Gossamer Bio Inc.(GOSS) Company Profile
Gossamer Bio, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutics in the disease areas of immunology, inflammation, and oncology in the United States. The company is developing GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colonystimulating factor 1 receptor, or CSF1R, and c-KIT inhibitor for the treatment of pulmonary arterial hypertension; GB004, a gut-targeted, oral small molecule for the treatment of inflammatory bowel disease; GB5121, an oral, irreversible, covalent, small molecule inhibitor of Bruton’s Tyrosine Kinase for the treatment of primary central nervous system lymphoma; and GB7208, an oral, small molecule, BTK inhibitor for the treatment of multiple sclerosis. It has license agreements with Pulmokine, Inc. to develop and commercialize GB002 and related backup compounds; and Aerpio Pharmaceuticals, Inc. to develop and commercialize GB004 and related compounds. The company was formerly known as FSG, Bio, Inc. and changed its name to Gossamer Bio, Inc. in 2017. Gossamer Bio, Inc. was incorporated in 2015 and is headquartered in San Diego, California.
Leave a Reply